Polaryx Therapeutics Inc (PLYX)
Featured in
Overvalued Stocks
Polaryx Therapeutics Inc. is a clinical-stage biotechnology company focused on developing disease-modifying treatments for rare and pediatric lysosomal storage disorders in the United States. The company’s pipeline includes PLX-100, an orally administered combination therapy in preclinical development; PLX-200, a repurposed oral small-molecule candidate for lysosomal storage disorders; PLX-300, another preclinical oral combination therapy; and PLX-400, a preclinical gene therapy program. Founded in 2014, Polaryx Therapeutics is based in Paramus, New Jersey, and its common stock trades on the NASDAQ under the ticker PLYX.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PLYX
|
$1.39
|
-40.7% Downside
|
Overvalued
|
$8.50
|
263.2% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-17.1x
|
44.5x
|
—
|
107 M
|
107.7 M
|
0.0%
|
9.0%
|
18.9
|
—
|
81.8%
|
